SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

(Amendment No.)				
Amylyx Pharmaceuticals, Inc.				
(Name of Issuer)				
Common Stock, par value \$0.0001 per share				
(Title of Class of Securities)				
03237H101				
(CUSIP Number)				
November 29, 2023				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
☐ Rule 13d-1(b)				
▼ Rule 13d-1(c)				
\square Rule 13d-1(d)				
(Page 1 of 8 Pages)				

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1	NAME OF REPORTING PERSON				
_	Point72 Accet Management, I. D.				
	Point72 Asset Management, L.P.				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)				
	(b) X				
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0			
	6	SHARED VOTING POWER 3,176,105			
	7	SOLE DISPOSITIVE POWER 0			
	8	SHARED DISPOSITIVE POWER 3,176,105			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,176,105				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.7%				
12	TYPE OF REPORTING PERSON PN				

1	NAME OF REPORTING PERSON					
-	Point72 Capital Advisors, Inc.					
2	CHECK THE A	(a) 🗆 (b) 🗵				
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0				
	6	SHARED VOTING POWER 3,176,105				
	7	SOLE DISPOSITIVE POWER 0				
	8	SHARED DISPOSITIVE POWER 3,176,105				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,176,105					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.7%					
12	TYPE OF REPORTING PERSON CO					

r	·					
1	NAME OF REPORTING PERSON					
_	Cubiat Systematic Strategies, LLC					
	Cubist Systematic Strategies, LLC					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
	(a) \square					
3	SEC USE ONL					
3						
4		CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware					
	5	SOLE VOTING POWER				
		0				
NUMBER OF SHARES	6	SHARED VOTING POWER				
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		294,586				
	7	SOLE DISPOSITIVE POWER				
	,	0				
	8	SHARED DISPOSITIVE POWER				
	8	294,586				
9	AGGREGATE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	294,586					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
10						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	0.4%					
12	12 TYPE OF REPORTING PERSON					
1 2	OO					

1	NAME OF REPORTING PERSON				
	Storian A. Cahan				
	Steven A. Cohen				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)				
	(b) ×				
3	SEC USE ONLY				
3					
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
•	United States				
	5	SOLE VOTING POWER			
		0			
NUMBER OF SHARES	6	SHARED VOTING POWER			
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	U	3,470,691			
	7	SOLE DISPOSITIVE POWER			
	,	0			
	8	SHARED DISPOSITIVE POWER			
		3,470,691			
9		AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	3,470,691				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
10					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	5.1%				
12		ORTING PERSON			
12	IN				

Item 1(a). Name of Issuer.

Amylyx Pharmaceuticals, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices.

43 Thorndike Street, Cambridge, Massachusetts 02141

Item 2(a). Name of Person Filing.

This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to shares of common stock, par value \$0.0001 per share ("Shares"), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC ("Cubist Systematic Strategies") with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.

Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

Item 2(b). Address of Principal Business Office.

The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

Item 2(c). Place of Organization.

Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr. Cohen is a United States citizen.

Item 2(d). Title of Class of Securities.

Common Stock, par value \$0.0001 per share

Item 2(e). CUSIP Number.

03237H101

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 8, 2023.

Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by a certain investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

See Item 2(a).

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the

Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: December 11, 2023

POINT72 ASSET MANAGEMENT, L.P.

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

POINT72 CAPITAL ADVISORS, INC.

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

CUBIST SYSTEMATIC STRATEGIES, LLC

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

STEVEN A. COHEN

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

EXHIBIT 99.1

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: December 11, 2023

POINT72 ASSET MANAGEMENT, L.P.

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

POINT72 CAPITAL ADVISORS, INC.

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

CUBIST SYSTEMATIC STRATEGIES, LLC

By: /s/ Jason M. Colombo Name: Jason M. Colombo Title: Authorized Person

STEVEN A. COHEN

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person